Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Nephrol Nurs J ; 37(4): 351-3, 356; quiz 354, 2010.
Article in English | MEDLINE | ID: mdl-20830942

ABSTRACT

Hemodialysis is widely acknowledged as a treatment option to stabilize acute medical conditions where biochemistry management is paramount. One of the most challenging situations is during liver transplantation, when patients with moderate renal dysfunction are likely to become acutely acidotic. For nephrology nurses, this extended role requires increased knowledge, advanced skills, and a high level of communication with unfamiliar team members. With appropriate procedures and a supportive environment, delivering such a service is feasible.


Subject(s)
Intraoperative Care/nursing , Liver Transplantation/nursing , Nurse's Role , Renal Dialysis/nursing , Australia , Clinical Competence , Communication , Humans , Intraoperative Care/methods , Kidney Failure, Chronic/therapy , Liver Transplantation/adverse effects , Liver Transplantation/statistics & numerical data , Nurse Clinicians/education , Nurse Clinicians/organization & administration , Patient Care Planning , Prescriptions , Professional Autonomy , Renal Dialysis/adverse effects , Renal Dialysis/methods , Renal Dialysis/statistics & numerical data
2.
BMC Nephrol ; 10: 23, 2009 Aug 20.
Article in English | MEDLINE | ID: mdl-19691852

ABSTRACT

BACKGROUND: Catheter-related bacteraemias (CRBs) contribute significantly to morbidity, mortality and health care costs in dialysis populations. Despite international guidelines recommending avoidance of catheters for haemodialysis access, hospital admissions for CRBs have doubled in the last decade. The primary aim of the study is to determine whether weekly instillation of 70% ethanol prevents CRBs compared with standard heparin saline. METHODS/DESIGN: The study will follow a prospective, open-label, randomized controlled design. Inclusion criteria are adult patients with incident or prevalent tunneled intravenous dialysis catheters on three times weekly haemodialysis, with no current evidence of catheter infection and no personal, cultural or religious objection to ethanol use, who are on adequate contraception and are able to give informed consent. Patients will be randomized 1:1 to receive 3 mL of intravenous-grade 70% ethanol into each lumen of the catheter once a week and standard heparin locks for other dialysis days, or to receive heparin locks only. The primary outcome measure will be time to the first episode of CRB, which will be defined using standard objective criteria. Secondary outcomes will include adverse reactions, incidence of CRB caused by different pathogens, time to infection-related catheter removal, time to exit site infections and costs. Prospective power calculations indicate that the study will have 80% statistical power to detect a clinically significant increase in median infection-free survival from 200 days to 400 days if 56 patients are recruited into each arm. DISCUSSION: This investigator-initiated study has been designed to provide evidence to help nephrologists reduce the incidence of CRBs in haemodialysis patients with tunnelled intravenous catheters. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry Number: ACTRN12609000493246.


Subject(s)
Anticoagulants/administration & dosage , Catheter-Related Infections/etiology , Catheter-Related Infections/prevention & control , Catheters, Indwelling/adverse effects , Ethanol/administration & dosage , Heparin/administration & dosage , Kidney Failure, Chronic/rehabilitation , Renal Dialysis/adverse effects , Humans , Kidney Failure, Chronic/complications , Treatment Outcome
3.
Am J Kidney Dis ; 54(1): 95-103, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19481320

ABSTRACT

BACKGROUND: Primary hepatitis B virus (HBV) vaccination through the intramuscular (IM) route is less efficacious in dialysis patients than in the general population. Previous studies suggest improved seroconversion with intradermal (ID) vaccination. STUDY DESIGN: Prospective open-label randomized controlled trial. SETTING & PARTICIPANTS: Hemodialysis patients nonresponsive to primary HBV vaccination. INTERVENTION: Revaccination with either ID (10 microg of vaccine every week for 8 weeks) [DOSAGE ERROR CORRECTED] or IM (40 microg of vaccine at weeks 1 and 8) HBV vaccine . PRIMARY OUTCOME: proportion of patients achieving HBV surface antibody (anti-HBs) titer of 10 IU/L or greater within 2 months of vaccination course. SECONDARY OUTCOMES: time to seroconversion, predictors of seroconversion, peak antibody titer, duration of seroprotection, and safety and tolerability of vaccine. MEASUREMENTS: Anti-HBs titer to 24 months. RESULTS: 59 patients were analyzed. Seroconversion rates were 79% ID versus 40% IM (P = 0.002). The unadjusted odds ratio for seroconversion for ID versus IM was 5.5 (95% confidence interval [CI], 1.6 to 18.4) and increased with adjustment for baseline differences. The only factor predictive of seroconversion was the ID vaccination route. The geometric mean peak antibody titer was significantly greater in the ID versus IM group: 239 IU/L (95% CI, 131 to 434) versus 78 IU/L (95% CI, 36 to 168; P < 0.001). There was a trend toward longer duration of seroprotection with ID vaccination. ID vaccine was safe and well tolerated. LIMITATIONS: Inability to distinguish whether the mechanism of the greater efficacy of ID vaccination was the cumulative effect of multiple injections or route of administration; use of anti-HBs as a surrogate marker of protection; lack of evidence of long-term protection. CONCLUSIONS: Significantly greater seroconversion rates and peak antibody titers can be achieved with ID compared with IM vaccination in hemodialysis patients nonresponsive to primary vaccination. ID vaccination should become the standard of care in this setting.


Subject(s)
Hepatitis B Vaccines/administration & dosage , Hepatitis B Vaccines/therapeutic use , Hepatitis B/prevention & control , Kidney Diseases/therapy , Renal Dialysis , Adult , Aged , Antibodies, Viral/blood , Chronic Disease , Female , Hepatitis B Vaccines/adverse effects , Humans , Injections, Intradermal , Injections, Intramuscular , Kaplan-Meier Estimate , Male , Middle Aged , Prospective Studies , Treatment Outcome
4.
Nephrology (Carlton) ; 12(3): 224-33, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17498116

ABSTRACT

BACKGROUND: Poor control of bone mineral metabolism (BMM) is associated with renal osteodystrophy and mortality in dialysis-dependent patients. The authors explored the efficacy of alternate nightly home haemodialysis (ANHHD) in controlling BMM parameters and its effects on bone mineral density and histomorphometry. METHODS: In this prospective observational study, 26 patients on home haemodialysis (3-5 h, 3.5-4 sessions weekly) were converted to ANHHD (6-9 h, 3.5-4 sessions weekly). Biochemical parameters of BMM at baseline, 6 and 12 months, radiological parameters at baseline and 12 months and bone histomorphometry at 12 months are described. RESULTS: Pre-dialysis serum phosphate fell from 2.13+/-0.65 to 1.38+/-0.35 mmol/L; P<0.0001. No binders were required in 77.2% compared with 7.7% at baseline. Calcium-phosphate product fell from 5.28+/-1.64 to 3.42+/-0.88 mmol2/L2; P<0.0001 and parathyroid hormone (PTH) from 301 (110-471) to 127 (47-240) ng/L; P=0.01. Bone mineral density remained stable. Vascular and ectopic calcification improved or stabilized in 87.5%. Bone histomorphometry at 12 months showed high, normal and low bone turnover in 10, 3 and 4 patients, respectively, with 6/17 patients having abnormal mineralization. CONCLUSION: Alternate nightly home haemodialysis effectively manages biochemical parameters of BMM. Patients with very high PTH at baseline (>1000 ng/L) did not significantly improve parathyroid hormone status. Abnormal bone turnover and mineralization were present in a significant proportion of patients at 12 months but low turnover was uncommon. Vascular calcification was stabilized or improved in the majority. ANHHD compares favourably with every night and short daily therapy in relation to BMM management and may offer lifestyle advantages for patients.


Subject(s)
Bone Density/physiology , Bone and Bones/anatomy & histology , Calcinosis/physiopathology , Hemodialysis, Home/methods , Peripheral Vascular Diseases/pathology , Renal Insufficiency/therapy , Absorptiometry, Photon , Calcium/blood , Electrolytes/blood , Extremities/blood supply , Extremities/diagnostic imaging , Female , Humans , Male , Middle Aged , Parathyroid Hormone/blood , Phosphates/blood , Prospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...